K
Kevin Ronald Condroski
Researcher at Celgene
Publications - 68
Citations - 2074
Kevin Ronald Condroski is an academic researcher from Celgene. The author has contributed to research in topics: Glucokinase & Transketolase. The author has an hindex of 21, co-authored 67 publications receiving 1899 citations. Previous affiliations of Kevin Ronald Condroski include University of California, Los Angeles & Hoffmann-La Roche.
Papers
More filters
Patent
Cell adhesion-inhibiting antiinflammatory compounds
Andrew O. Stewart,Steven A. Boyd,David L. Arendsen,Pramila Bhatia,Kevin Ronald Condroski,Jennifer C. Freeman,Gunawardana Indrani W,Zhu Gui-Dong,Lartey Kraig,Mccarty Catherine M,Mort Nicholas A,Meena V. Patel,Staeger Michael A,David M. Stout +13 more
TL;DR: In this article, pharmaceutical compositions comprising compouns of Formula (I) and methods of inhibiting/treating inflammatory diseases in a mammal are discussed, and they are shown to be useful for treating inflammation.
Journal ArticleDOI
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Scott D. Seiwert,Andrews Steven W,Jiang Yutong,Vladimir Serebryany,Hua Tan,Karl Kossen,P. T. Ravi Rajagopalan,Shawn Misialek,Sarah K. Stevens,Antitsa Dimitrova Stoycheva,Jin Hong,Sharlene R. Lim,Xiaoli Qin,Robert Rieger,Kevin Ronald Condroski,Hailong Zhang,Mary Geck Do,Christine Lemieux,Gary P. Hingorani,Dylan P. Hartley,John A. Josey,Lin Pan,Leonid Beigelman,Lawrence M. Blatt +23 more
TL;DR: The preclinical characteristics of ITMN-191, a peptidomimetic inhibitor of the NS3/4A protease of HCV, compare favorably to those of other inhibitors of NS3 /4A in clinical development and therefore support the clinical investigation of IT MN-191 for the treatment of chronic hepatitis C.
Journal ArticleDOI
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin Solomon,Lavinia Tan,Jessica J. Lin,Stephen Q. Wong,Sebastian Hollizeck,Kevin Ebata,Brian B. Tuch,Satoshi Yoda,Justin F. Gainor,Lecia V. Sequist,Geoffrey R. Oxnard,Oliver Gautschi,Alexander Drilon,Vivek Subbiah,Christine Khoo,Edward Y. Zhu,Michele Nguyen,Dahlia Henry,Kevin Ronald Condroski,Kolakowski Gabrielle R,Eliana B. Gomez,Joshua Ballard,Andrew T. Metcalf,James F. Blake,Sarah-Jane Dawson,Wayne Blosser,Louis Stancato,Barbara J. Brandhuber,Steve Andrews,Bruce G. Robinson,S. Michael Rothenberg +30 more
TL;DR: Analysis of circulating tumor DNA revealed emergence of RET G810R, G810S, and G810C mutations in the RET solvent front before the emergence of clinical resistance, which represents the first described recurrent mechanism of resistance to selective RET inhibition with selpercatinib.
Journal ArticleDOI
Transition States of Epoxidations: Diradical Character, Spiro Geometries, Transition State Flexibility, and the Origins of Stereoselectivity
TL;DR: The transition structures for the epoxidations of ethylene by performic acid, dioxirane, oxaziridine, and peroxynitrous acid have been located with density functional theory methods using the Becke3LYP functional and 6-31G* basis set as discussed by the authors.
Patent
Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors
Shelley Allen,Andrews Steven W,Kevin Ronald Condroski,Julia Haas,Huang Lily,Jiang Yutong,Timothy Kercher,Jeongbeob Seo +7 more
TL;DR: In this article, the authors describe compounds of formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.